Inflammatory biomarkers in Alzheimer's disease plasma - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Alzheimer's & Dementia : the Journal of the Alzheimer's Association Année : 2019

Inflammatory biomarkers in Alzheimer's disease plasma

1 Cardiff University
2 University of Oxford
3 VU University Medical Center [Amsterdam]
4 UCL - University College of London [London]
5 MPIMG - Max Planck Institute for Molecular Genetics
6 INS - Institut de Neurosciences des Systèmes
7 APHM - Assistance Publique - Hôpitaux de Marseille
8 Maastricht University [Maastricht]
9 Universität zu Lübeck = University of Lübeck [Lübeck]
10 Institute Born-Bunge [Antwerp, Belgium]
11 UNIGE - Université de Genève = University of Geneva
12 Istituto Centro San Giovanni di Dio Fatebenefratelli
13 Universität Heidelberg [Heidelberg] = Heidelberg University
14 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
15 Karolinska Institutet [Stockholm]
16 GU - Göteborgs Universitet = University of Gothenburg
17 MUL - Medical University of Łódź
18 Imperial College London
19 Hospital de la Santa Creu i Sant Pau
20 Center for Research and Advanced Therapies CITA-Alzheimer Foundation [San Sebastián]
21 UNIPG - Università degli Studi di Perugia = University of Perugia
22 UPF - Universitat Pompeu Fabra [Barcelona]
23 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
24 HUG - Hôpitaux Universitaires de Genève
25 GSK - GlaxoSmithKline [Stevenage, UK]
26 Amsterdam UMC - Amsterdam University Medical Center
27 VU - Vrije Universiteit Amsterdam [Amsterdam]
28 UA - University of Antwerp
29 University of Eastern Finland
30 University Hospitals Leuven [Leuven]
31 AHEPA University General Hospital [Thessaloniki]
32 Sahlgrenska Academy at University of Gothenburg [Göteborg]
33 Sahlgrenska University Hospital [Gothenburg]
34 UCL Queen Square Institute of Neurology
Claire Leckey
  • Fonction : Auteur
Alberto Lleó
Pieter Jelle Visser

Résumé

Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Domaines

Neurosciences

Dates et versions

hal-03598014 , version 1 (04-03-2022)

Identifiants

Citer

Angharad Morgan, Samuel Touchard, Claire Leckey, Caroline O'Hagan, Alejo Nevado‐holgado, et al.. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 2019, 15 (6), pp.776-787. ⟨10.1016/j.jalz.2019.03.007⟩. ⟨hal-03598014⟩
31 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More